COYA logo

COYA THERAPEUTICS INC

COYANASDAQ
🏆 #4022 by market capEarnings Nov 10US Equity
$1,002.32▲ $18.84 (+1.88%)
Simulated price
🔔
Track COYA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$118M
Small Cap
📈Revenue Growth (YoY)
+123.6%
High Growth
📊Gross Margin
99.9%
High
💵FCF Margin
-170613.5%
Thin
⚖️P/S Ratio
14.8x
Expensive
Otter Score
60
Fair
No chart data available for COYA.

Trading Snapshot

Day Range
$986.43 – $1,021.89
52-Week Range
$3.71 – $7.75
Volume
$3.86B
Avg Volume
$4.34B
Shares Outstanding
23.5M
Next Earnings
Nov 16, 2026

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
$243,745
P/E Ratio
-4.7
P/S Ratio
14.8x
EPS (TTM)
$-0.92
Dividend Yield
0.00%
Dilution (1yr)
+2.3%

Why Investors Own COYA

  • ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

COYA logo

COYA THERAPEUTICS INC

COYA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$8M▲ +123.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.7%▼ −142.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$20M▲ +17.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▲ +4.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
16.7M▲ +2.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$47M▲ +$8M YoY
StockOtter · stockotter.space

About COYA THERAPEUTICS INC

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$1,223.54
▲ +22.1% Upside
High Target$1,536.18
Low Target$925.35
Based on 20 analysts

Latest News & Updates

🚀
Barron’s·2h ago

COYA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift COYA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

COYA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.